Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jun;54(2):120-131.
doi: 10.1111/vcp.70017. Epub 2025 Jun 16.

Comparison of Hemostatic Activity in Canine Leukoreduced Cryoprecipitate, Cryopoor Plasma, and Fresh Plasma

Roberta Perego  1 , Eva Spada  1 , Luciana Baggiani  1 , Giuliano Ravasio  2 , Enrica Zucca  2 , Graziella Vanosi  2 , Giancarlo Ruffo  2 , Daniela Proverbio  1
Affiliations
Comparative Study

Comparison of Hemostatic Activity in Canine Leukoreduced Cryoprecipitate, Cryopoor Plasma, and Fresh Plasma

Roberta Perego et al. Vet Clin Pathol. 2025 Jun.

Abstract

Background: To date, no studies have reported the evaluation of hemostatic activity in canine leukoreduced cryoprecipitate (LR-CRYO) and leukoreduced cryopoor plasma (LR-CPP).

Objectives: We aimed to compare the hemostatic activity of LR-CRYO and LR-CPP to leukoreduced fresh plasma (LR-FP) and to evaluate the preservation of LR-CRYO by refrigeration and refreezing after thawing.

Methods: Four hundred fifty milliliters of fresh blood was collected from ten donor dogs, leukoreduced, and separated into LR-FP, then frozen (-20°C) to obtain leukoreduced fresh frozen plasma (LR-FFP). LR-FFP was further separated into LR-CRYO and LR-CPP. LR-CRYO was frozen, thawed, and divided into two bags, one refrigerated for 24 h and one refrozen for 7 days. Factor VIII (FVIII) and X (FX) activity, prothrombin time, activated partial thromboplastin time, antithrombin III (ATIII) activity (ATA), total protein, albumin, fibrinogen, and D-dimer concentration, and von Willebrand Factor (vWF) activity were measured in LR-FP, LR-CRYO, LR-CPP, refrigerated, and refrozen LR-CRYO.

Results: FVIII activity was higher in LR-CRYO (p = 0.0001) versus LR-FP. vWF activity (p < 0.0001) and fibrinogen concentration (p = 0.0012) were lower in LR-CPP versus LR-FP. FX activity was higher in LR-CPP (p < 0.0001) and LR-FP (p = 0.0002) versus LR-CRYO, and albumin concentration was higher in LR-CPP versus LR-FP (p < 0.0001) and LR-CRYO (p < 0.0001). No statistically significant difference was found in refrigerated or refrozen LR-CRYO as compared with LR-CRYO, excluding ATA, which was lower (p = 0.0062) in refrigerated LR-CRYO.

Conclusions: Because the concentration of FVIII is higher in LR-CRYO than in LR-FP, LR-CRYO is a possible component therapy when this factor is deficient. Since no statistically significant difference was found in refrozen LR-CRYO as compared with LR-CRYO, LR-CRYO can be frozen after thawing for reuse.

Keywords: blood components; dog; factor VIII; factor X; leukoreduction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Schematic flowchart of study design.
FIGURE 2
FIGURE 2
Box and whisker plots of some activity levels and concentrations measured for each unit of LR‐fresh plasma (LR‐FP), LR‐cryoprecipitate (LR‐CRYO) and LR‐cryopoor plasma (LR‐CPP). (A) Factor VIII activity levels, Y‐axis represent %, (B) factor X activity levels, Y‐axis represent %, (C) Von Willbrand VIII activity levels, Y‐axis represent %, (D) fibrinogen concentrations, Y‐axis represent mg/dL, (E) total protein concentrations, Y‐axis represent g/L, and (F) albumin concentrations, Y‐axis represent g/L.
FIGURE 3
FIGURE 3
Mean relative difference in analyte levels in leukoreduced cryoprecipitate (LR‐CRYO) and leukoreduced cryopoor plasma (LR‐CPP) from leukoreduced fresh plasma (LR‐FP) depicted as baseline values. PT: prothrombin time; aPTT: activated partial thromboplastin time; FVIII: factor VIII; FX: factor X; ATA: antithrombin III activity; vWF: factor von Willebrand. Asterisks* denote significant difference (p < 0.05) compared with LR‐FP level.
See this image and copyright information in PMC

References

    1. Prittie J., “The Role of Cryoprecipitate in Human and Canine Transfusion Medicine,” Journal of Veterinary Emergency and Critical Care 31, no. 2 (2021): 1–11, 10.1111/vec.13034. - DOI - PubMed
    1. Drinkhouse M., Brooks M. B., Stefanovski D., Marryott K., and Callan M. B., “Influence of Canine Donor Plasma Hemostatic Protein Concentration on Quality of Cryoprecipitate,” Journal of Veterinary Internal Medicine 33, no. 1 (2019): 124–131, 10.1111/jvim.15376. - DOI - PMC - PubMed
    1. Sparrow R. L., Greening D. W., and Simpson R. J., “A Protocol for the Preparation of Cryoprecipitate and Cryodepleted Plasma,” Methods in Molecular Biology 728 (2011): 259–265, 10.1007/978-1-61779-068-3_17. - DOI - PubMed
    1. Ching Y. N. L. H., Meyers K. M., Brassard J. A., and Wardrop K. J., “Effect of Cryoprecipitate and Plasma on Plasma von Willebrand Factor Multimeters and Bleeding Time in Doberman Pinschers With Type‐I von Willebrand's Disease,” American Journal of Veterinary Research 55, no. 1 (1994): 102–110. - PubMed
    1. Sparrow R. L., Simpson R. J., and Greening D. W., “Preparation of Cryoprecipitate and Cryo‐Depleted Plasma for Proteomic Research Analysis,” Methods in Molecular Biology 2628 (2023): 41–49, 10.1007/978-1-0716-2978-9_4. - DOI - PubMed

Publication types